DermTech, Inc. provided revenue guidance for the full year 2022. For the period, the company expects assay revenue to be between $16 million and $19 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1142 USD | -3.14% |
|
-64.18% | -93.47% |
Jun. 20 | Motion for Joint Administration Approved for DermTech, Inc. | CI |
Jun. 18 | Sector Update: Health Care Stocks Edge Up Late Afternoon | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-93.47% | 3.99M | |
-11.68% | 11.22B | |
-10.38% | 7.58B | |
+27.58% | 5.48B | |
+1.44% | 5.38B | |
-17.38% | 3.77B | |
+8.12% | 2.6B | |
-64.90% | 2.35B | |
+26.75% | 2.2B | |
-12.53% | 1.7B |
- Stock Market
- Equities
- DMTK Stock
- News DermTech, Inc.
- Dermtech, Inc. Provides Revenue Guidance for the Full Year 2022